Acme United Q2 Earnings Beat Driven by MyMedic Acquisition and Margin Expansion

• Acme United Corporation (ACU) reported Q2 2026 earnings per share (EPS) of $1.22, significantly exceeding analyst estimates of $0.81 and driving an 11.92% to 17.52% surge in its stock price.
• Revenue reached $62.7 million against forecasts of $58.1 million, reflecting a 16% year-over-year increase primarily fueled by the integration of the MyMedic acquisition.
• Gross margins expanded to 42.6% from 41.0% in the prior year period, signaling improved operational leverage and cost management capabilities.
• Management anticipates continued margin recovery as the company transitions from higher-tariff inventory to lower-cost stock, with strong profitability expected in Q4.
• Investors should monitor elevated selling, general, and administrative (SG&A) expenses at 32% of sales, alongside potential tariffs and uneven geographic performance in Canada.

Acme United Corporation delivered robust financial results for the second quarter of 2026, marking a significant departure from prior year performance. The company reported diluted earnings per share of $1.22, representing a substantial 50.62% beat against the consensus estimate of $0.81. This strong performance was mirrored in the top line, with total revenue reaching $62.72 million, surpassing forecasts of $58.08 million by nearly 8%. The market reacted swiftly to these figures, with shares surging approximately 11.92% to 17.52% following the report, pushing the stock near its 52-week high of $51.88. The underlying drivers of this growth were identified as both acquisition integration and improved operational efficiency.

How Did the MyMedic Acquisition Drive Growth?

The acquisition of MyMedic served as the primary catalyst for Acme United’s top-line expansion during the quarter. The company reported a 16% year-over-year increase in sales, a figure largely attributed to the inclusion of MyMedic’s results in the consolidated financials. When excluding the impact of this acquisition, Acme United still demonstrated solid organic growth of 8%, indicating underlying strength in its core operations. This dual layer of growth—organic and acquisitive—provided a comprehensive view of the company’s expanding market presence.

Management, led by CEO Johnsen, highlighted that the integration of MyMedic is an ongoing process with strategic implications for future distribution. The company is actively working to expand the MyMedic brand beyond its established direct-to-consumer channels into mass retail markets. This strategic pivot is expected to unlock additional revenue streams and enhance brand visibility. Furthermore, the company anticipates strong profitability in the fourth quarter, driven by seasonal demand patterns that typically benefit the emergency medical and consumer safety sectors.

What Are the Prospects for Margin Recovery?

Profitability metrics improved significantly in Q2 2026, with gross margins expanding to 42.6% from 41.0% in the prior year period. This expansion underscores improved pricing power and effective cost management. Operational efficiency also contributed to robust earnings before interest, taxes, depreciation, and amortization (EBITDA), which stood at $8.801 million, reflecting a 136.78% growth rate compared to the prior year. The EBITDA margin expanded to 14.03%, indicating that the company is successfully navigating cost pressures to deliver exceptional bottom-line results.

Looking ahead, management provided optimistic guidance regarding the margin trajectory. CEO Johnsen noted that tariff pressures are expected to ease as the company transitions from higher-tariff inventory to lower-cost stock by the end of the year. This inventory transition is a critical factor in sustaining the margin expansion observed in Q2. The company’s financial structure suggests a phase of high growth, prioritizing reinvestment and operational scaling over immediate shareholder distributions, as no dividends were declared for this period.

What Risks and Headwinds Persist?

Despite the positive results, several risks and headwinds warrant investor attention. Selling, general, and administrative (SG&A) expenses remain elevated at 32% of sales, which could pressure net income if not managed effectively. The company also faces ongoing volatility from potential tariff and freight cost fluctuations, as well as currency headwinds that could impact international revenue.

Geographic performance remains uneven, with Canada currently lagging behind other regions. This disparity highlights the challenges of maintaining consistent global growth in diverse regulatory and economic environments. Additionally, while Acme United exhibits strong liquidity with a current ratio of 3.23, well above the industry average of 2.33, its profitability metrics trail industry peers. However, recent trends show improvement, with the most recent quarter EPS growing 5.17% year-over-year, outpacing the industry’s 1.44% growth. This suggests that operational efficiencies and acquisition synergies are beginning to translate into bottom-line improvements, potentially narrowing the gap with industry peers in upcoming quarters.

The stock’s lower beta of 0.49, roughly half the industry average of 0.85, indicates that it is less volatile than the broader market. This lower volatility, combined with a modest dividend yield of 1.20%, positions the stock as a relatively stable holding. Investors monitoring Acme United should focus on the successful execution of the MyMedic integration and the anticipated easing of tariff pressures as key indicators of sustained future performance.